Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT02283853 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

156

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

DRUG: dimethyl fumarate
DRUG: Interferon β-1a

Sponsor

Biogen